VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

February, 22 2023

BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts, on March 7, 2023. Management will also be available for 1-on-1 meetings with investors. 43rd Annual Cowen Health Care Conference Presentation Details Fireside Chat: Tuesday, March 7th, 2023, at 2:10 PM ET Speaker: David…

Read More

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

December, 12 2022

BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for one-on-one meetings. One-on-One Meeting Details Meeting Dates: January 10-11, 2023 Location: Beacon Grand Hotel Format: 1-on-1, in-person meetings *For more information or to request a meeting please register here About VYNE…

Read More

VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

December, 02 2022

BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022. Panel Presentation Details Date: Thursday, December 8, 2022 Time: 10:00 to 10:45 a.m. ET Panel Presentation: Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus Presenter: David Domzalski, President and Chief Executive Officer…

Read More

VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

November, 18 2022

BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on December 1, 2022. Piper Sandler 34th Annual Healthcare Conference Date: Thursday, December 1, 2022 Time: 12:30 p.m. ET Format: Company presentation 1×1 Meetings: Thursday, December 1, 2022 Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1582698&tp_key=84bac10d55 a replay will…

Read More

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

May, 10 2022

BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it will hold a virtual Key Opinion Leader (KOL) event on VYNE’s InhiBET™ BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m. ET. The agenda for the webinar will include an overview on pan-bromodomain and extra-terminal (“BET”) inhibition for the treatment of various immuno-inflammatory conditions, a review of the current treatment landscape and unmet medical need in treating patients with vitiligo, a discussion…

Read More

VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th

May, 06 2022

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10th-11th, 2022. Virtual Presentation Details     Date: Tuesday, May 10th Time: 1:30pm Eastern Time Webcast Link: VYNE Therapeutics Presentation The replay of the webcast will be available on the VYNE website for 90 days following the conference. About VYNE…

Read More